Claims
- 1. A full-length infectious cDNA clone of Langat tick-borne flavivirus.
- 2. The clone of claim 1, wherein said Langat is Langat strain TP21.
- 3. The clone of claim 1, wherein said Langat is Langat strain E5.
- 4. The clone of claim 1, further comprising at least one virulence-reducing mutation, whether spontaneously arising or genetically engineered.
- 5. The clone of claim 1, incorporated within a vector.
- 6. The clone of claim 5, wherein said vector is a plasmid.
- 7. A prokaryotic host cell stably transformed with the clone of claim 1.
- 8. A full-length infectious RNA transcribed from a stable, full-length cDNA clone of Langat tick-borne flavivirus.
- 9. A eucaryotic host cell infected with the RNA of claim 8.
- 10. A virus produced from the host cell of claim 9.
- 11. A unit dose of an immunogenic composition comprising the virus of claim 10.
- 12. A method of inducing an immune response comprising the step of administering the unit dose of claim 11 to a vaccinee.
- 13. A method of making a stable full-length infectious cDNA clone of Langat tick-borne flavivirus comprising as a first step the step of harvesting a Langat tick-borne flavivirus suspension early in the growth cycle to minimize the frequency of deletion mutants that accumulate late in infection.
- 14. The method of claim 13, wherein the viral titer of the flavivirus suspension is about 3.8×103 PFU.
- 15. A unit dose of a vaccine comprising the virus of claim 10.
- 16. A method of inducing protective immunity comprising the step of administering the unit dose of claim 15 to a vaccinee.
- 17. The clone of claim 1 further comprising the mutations from TP21-636.
- 18. The clone of claim 1 further comprising the mutations from TP21-649.
- 19. The clone of claim 1 further comprising the mutations from TP21-656.
- 20. The clone of claim 1 further comprising the mutations from TP21-689.
- 21. The clone of claim 1 further comprising the mutations from E5-651.
- 22. The clone of claim 1 further comprising the mutations from E5-3′-320.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of international application number PCT/US01/04460, and claims the benefit of priority of international application number PCT/US01/04460 having international filing date of Feb. 9, 2001, designating the United States of America and published in English, which claims the benefit of priority of U.S. provisional patent application No. 60/181,490, filed Feb. 10, 2000; both of which are hereby expressly incorporated by reference in their entireties.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60181490 |
Feb 2000 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
PCT/US01/04460 |
Feb 2001 |
US |
Child |
10207745 |
Jul 2002 |
US |